Relay Medical Corp: The Real Winner Behind The Travel Industry Reboot

By Jason Eckerman


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Travel Industry Making A Comeback


With the COVID-19 vaccine supply ramping up, the travel industry is finally set to boom once again.

That’s because many are expecting a huge bounce back with all the pent-up demand from consumers desperate to go on the vacations they’ve delayed over the last year.

But the gains have already started early, and those in the cruise industry in particular have been eye-popping.

Norwegian Cruise Line Holdings is up 210% from last year’s lows.

Carnival Corp. has jumped an incredible 224%.

And Royal Caribbean Group has soared 242%.

That puts these gains at nearly 4x what the S&P 500 has returned on a remarkable year over that time.

Keep in mind, that’s all while most cruise ships are still landbound.

And now that there’s a light at the end of the tunnel, the biggest investment banks are all showing their support for this corner of the markets too.

JP Morgan, for example, just raised their price targets on several of the main cruise lines.

And one of their analysts said, “We are bullish on the industry’s pending recovery, owing to what is expected to be a strong U.S. consumer spending environment and sizable pent-up leisure travel demand […].”

But even with the boom in vaccine supply, there’s one key piece missing that will allow the cruise industry to open confidently.

DOWNLOAD OUR SPECIAL REPORT on Relay’s breakthrough rapid testing technology and how early investors could profit.

Rapid testing for COVID-19, its variants, and other infectious diseases is a must to help people put to rest their fears of traveling on these self-contained vessels.

That means providing a solution that doesn’t just ensure passengers are testing negative a few days before boarding, but right as they’re getting ready to step foot on the ship.

That’s why Relay Medical’s recent announcement is such an exciting one, as they prepare to provide the cruise industry with the support they so desperately need.

Relay has launched the Fionet Pandemic Testing Platform.

Relay has already become well-known as an IoT (internet of things) technology company, with a reputation for helping the next generation of HealthTech breakthroughs.

And with their rapid testing platform, Fionet, they’re helping to stop the spread of COVID-19 and playing a major role in re-opening the world again.

It could be the master key we’ve been searching for to unlock the travel industry as a whole.

Relay just announced that they’ve added 3 strategic advisors to help support the cruise industry and the CARICOM Region (Caribbean Community and Common Market).

CARICOM member countries see up to 30 million international tourists each year, making it the highest GDP-generating travel and tourism destination in the world.

And now Relay aims to bring this proven technology to the CARICOM region and the cruise industry to help light the fuse on the industry boom we’ve all been waiting for.

They recently announced they’ve brought on Bernard O’Brien, who has been a respected leader at Carnival Cruise Line for 12 years.

During that time, he helped implement the first 100% Wi-Fi cruise ships.

And Relay expects that his expertise will also help them confidently introduce Fionet to deliver real-time intelligence for cruise ships of all sizes.

In addition, they’ve brought Donal Smith and Keith Davis on as strategic advisors for their combined experience in the CARICOM region spanning nearly 40 years.

With their leadership in government in the Caribbean, they’re in the perfect position to help Relay identify and execute on opportunities across the region.

That includes potentially providing this technology across communities, businesses, and public health sectors.

This could be the missing piece of the puzzle to not just help the cruise industry, but one of the biggest tourism destinations in the world, get back on their feet together.

This would be the latest of a long list of accomplishments for the Fionet technology.

It’s already a proven solution that’s been used all over the world in managing epidemics in the past.

But just recently, they’ve signed another major agreement that is putting the Fionet technology inside a major travel hub.

Relay announced they’re rolling out Fionet to be used at the Toronto Airport, the largest international airport in Canada.

With over 50 million people passing through the airport in 2019, Fionet will support rapid testing to ensure both the safety of employees and passengers.

In fact, Relay recently announced that they’ve just deployed the technology, and it’s already being used to manage the rapid testing at this massive travel hub at this very moment.

This is major news for Relay as all air passengers coming into Canada are required to provide confirmation of negative test results to enter the country.

Plus, even with the vaccine rollout, many countries are requiring negative test results in order to be allowed into the country.

And as 1 of only 4 international airports in the country, this means many will require this technology to help enter the country and travel safely.

Plus, with the CDC now mandating all passengers coming into the U.S. be required to provide negative test results as well, it will also provide testing for those flying out of Toronto to destinations accepting Antigen RDTs.

Together, Fionet could be used to test millions of passengers over the next year alone.

It could be exactly what we need to start traveling, enjoying long-awaited vacations and seeing distant family members again.

Proven Tech With Big-Name Support


Fionet has already received validation from some of the leading health organizations in the world.

That includes working with the World Health Organisation (WHO), the CDC, the Department of Defense (DoD), DARPA, the Walter Reed Army Institute of Research, and the Bill and Melinda Gates Organization…

And Fionet has been used to test and monitor the spread of such deadly diseases as malaria, HIV, Ebola, and dengue fever.

Most recently, Canada’s most established lab, LifeLabs LP, signed an agreement to deploy the Fionet platform shortly.

LifeLabs is Canada’s largest provider of specialty laboratory testing services, laboratory diagnostic information and digital health connectivity systems, enabling patients and healthcare practitioners to diagnose, treat, monitor, and prevent disease.

The company supports 20 million patient visits annually and conducts over 100 million laboratory tests through leading edge technologies and its 6,000 employees.

LifeLabs will provide the Fionet Platform in community-based settings at multiple sites across Canada, which may include airports, pop-up labs, and installations for small businesses.

The Fionet Platform will be integrated into LifeLabs’ laboratory information system, ensuring seamless interoperation.

And it will also be integrated into LifeLabs’ turnkey, end-to-end COVID-19 rapid diagnostic testing (RDT) program to support Canadians as they return to work.

That’s because Fionet helps provide fast, accurate test results within minutes in the field, along with everything you need to coordinate the testing, such as:

  • Fast and easy scheduling

  • Test results returned in as little as 15 minutes

  • Data sent securely to the cloud to integrate with healthcare systems

  • Alerting healthcare workers, in order to begin isolation protocols or deploy resources if positive cases are found

This is the perfect solution for high-traffic locations like travel hubs, sports arenas, and event centers…

And it could soon be used in schools and businesses to bring everyone safely back to the classrooms and offices again.

Thanks to the support from major health organizations, Fionet has received the validation and backing that has helped put the technology into major hubs.

And thanks to their latest acquisition in the cybersecurity space, Relay will not only be supporting Fionet in the medical sector but expanding into other industries as well.

CLICK HERE TO DOWNLOAD OUR SPECIAL REPORT NOW and discover why early investors are so confident Relay’s will dominate the growing health tech market.

Cybeats is a leading-edge IoT and connected device security company, and this acquisition will be a major addition to Relay’s growing product line given how quickly Fionet has taken off recently.

The Cybeats technology could even see more applications with upcoming launches of other products in the $73 billion IoT security market as well.

That includes supporting Relay’s products as well as being made available for commercial use with original equipment manufacturer (OEM) and original design manufacturer (ODM) companies who can then integrate Cybeats into their own products.

This breakthrough technology helps companies spot security gaps in their devices and their software supply chain.

That means they could use this with their Fionet technology to ensure that all test results are completely secure and that this health data is protected from any outside threats.

Because of Cybeats’ unique inside-to-out approach, it helps identify security issues in real-time and allows you to respond to the problem without any downtime.

This will be an incredible boost to support Fionet and other IoT technologies as the growth of connected devices continue to accelerate across North America and beyond.

With Fionet becoming a key piece of reopening travel at Canada’s largest airport, Relay’s latest move could be the next step in re-opening travel across the globe.

And thanks to the addition of these key strategic advisors, Relay could soon use this technology to lead the resurgence of the cruise lines in the world’s biggest tourism destination.



This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Relay Medical to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of three hundred and twenty-five thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.


In this article:


Author: Jason Eckerman

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Jason Eckerman does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Jason Eckerman has been paid to produce this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter